Navigation Links
Opsona Therapeutics Closes EUR18M Funding
Date:2/18/2009

and wellness focused venture capital funds, with the resources to provide continued support to growing companies.

http://www.inventages.com

About Seroba Kernel Life Sciences

Seroba Kernel is a dedicated life science venture capital fund manager with offices in Ireland and the UK. The firm recently announced the first close of Seroba Kernel Life Sciences Fund II with EUR75m in committed capital, bringing total funds under management by the six-member team in the life science sector to over EUR200m. The fund will invest in European life science companies with the majority of its capital invested in Ireland and the UK.

   http://www.seroba-kernel.com
    For media queries please contact:
    Niamh Lyons - +353-1-6633602
    or
    Jonathan Birt - +44-20-7269-7205

'/>"/>
SOURCE Opsona Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four ... million and provides a good start to Q4.  The orders are ... and one in the Middle East . ... said Peter Bruijns , President & CEO. "Total bidding activity ... they have been for any complete year since the company has ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report ... with analysis and forecast of revenue. This market is ... $208 million by 2019, at a Compound Annual Growth ... Browse through the TOC of the Asia-Pacific Speech Analytics ... analysis provided. It also provides a glimpse of the ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... PARIS and LAUSANNE, Switzerland, September 7 ... Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical,group of ... prescription drugs that,target unmet medical needs, announced today ... granted an exclusive worldwide license to develop,and commercialise ...
... manufacture hydroxyapatite (HA) could be used to make stronger, ... University of Birmingham this week (7-10 September) presented work ... University, Edinburgh. Using Serratia bacteria, the ... surfaces such as titanium alloy, polypropylene, porous glass and ...
... Sept. 6 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... biotechnology company,focused on researching, developing, manufacturing and marketing,biopharmaceutical ... of,shareholders of 3SBio Inc. will be held on ... No.3 A1, Road 10, Shenyang Economy & Technology ...
Cached Biology Technology:Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 2Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 3Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 4Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 53SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009 2
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/15/2014)... Alt will be awarded the 44th Rosenstiel Award for ... his pioneering research exploring the mechanisms of genomic instability ... cells. Alt is the second alumnus to win the ... Prize in 2003. , Alt is the Charles A. ... Harvard Medical School and an investigator at the Howard ...
(Date:10/14/2014)... N.C. – Like discriminating thieves, prostate cancer tumors scavenge ... the body. But such avarice may be a fatal ... a way to kill prostate cancer cells by delivering ... selectively destroys the diseased cells brimming with the mineral, ... uses two drugs already commercially available for other uses, ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
... Rainmakers, Inc., an intellectual property holding company and advanced ... its "stealth" mode and is prepared to actively commercialize ... security offerings. , During the past four years, the ... develop and deploy a series of core--but expandable--technologies built ...
... up 45 percent of blood, normally take the shape of ... can sometimes deform into an asymmetrical slipper shape. A ... flow might be responsible for this deformation, as well as ... could help understand the mechanisms involved in arterial disease and ...
... CAMDEN Contrary to a national trend, more and ... major in math and science. Thanks to a $307,277 ... students in the sciences at RutgersCamden will receive unprecedented ... of their degrees. Through a new RutgersCamden program ...
Cached Biology News:Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3NSF grant supports Rutgers-Camden program for science majors 2NSF grant supports Rutgers-Camden program for science majors 3
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
... PAGE Cleavable ICAT Reagent ... Protein ID and Quantitation ... Electrophoresis (PAGE), isotope-coded affinity ... technology to facilitate the ...
Supplemental reagent for annexin V assay....
Biology Products: